Cargando…

Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients

In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality. In laboratory studies, metformin was reported to affect the survival of cancer stem cells (CSCs) in breast and pancreatic cancers and glioblastoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yanfei, Guan, Meiping, Zheng, Zongji, Zhang, Qian, Gao, Fang, Xue, Yaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836781/
https://www.ncbi.nlm.nih.gov/pubmed/24278407
http://dx.doi.org/10.1371/journal.pone.0081264
_version_ 1782292348724576256
author Zhang, Yanfei
Guan, Meiping
Zheng, Zongji
Zhang, Qian
Gao, Fang
Xue, Yaoming
author_facet Zhang, Yanfei
Guan, Meiping
Zheng, Zongji
Zhang, Qian
Gao, Fang
Xue, Yaoming
author_sort Zhang, Yanfei
collection PubMed
description In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality. In laboratory studies, metformin was reported to affect the survival of cancer stem cells (CSCs) in breast and pancreatic cancers and glioblastoma. Although cscs play a critical role in the resistance to 5-fluorouracil (5-FU) chemotherapy in CRC patients, the effect of metformin on cscs in CRC patients and the synergistic effect of metformin in combination with 5-FU on cscs are not reported. In the present study pathological examinations were performed in 86 CRC patients complicated with type 2 DM who had been divided into a metformin group and a non-metformin group. Comparisons regarding pathological type, incidence of metastasis, expression of CD133 and β-catenin were conducted between the two groups. We explored the synergistic effects of metformin in combination with 5-FU on the proliferation, cell cycle, apoptosis and the proportion of CD133+ cscs of SW620 human colorectal cancer cell lines. The results show that metformin treatment had reverse correlations with the proportion of patients with poorly differentiated adenocarcinoma, the proportion of CD133+ cscs in CRC patients with type 2 DM. Metformin enhanced the antiproliferative effects of 5-FU on CD133+ cscs in SW620 cells. These findings provide an important complement to previous study. Inhibition of the proliferation of CD133+ cscs may be a potential mechanism responsible for the association of metformin use with improved CRC outcomes in CRC patients with type 2 diabetes.
format Online
Article
Text
id pubmed-3836781
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38367812013-11-25 Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients Zhang, Yanfei Guan, Meiping Zheng, Zongji Zhang, Qian Gao, Fang Xue, Yaoming PLoS One Research Article In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality. In laboratory studies, metformin was reported to affect the survival of cancer stem cells (CSCs) in breast and pancreatic cancers and glioblastoma. Although cscs play a critical role in the resistance to 5-fluorouracil (5-FU) chemotherapy in CRC patients, the effect of metformin on cscs in CRC patients and the synergistic effect of metformin in combination with 5-FU on cscs are not reported. In the present study pathological examinations were performed in 86 CRC patients complicated with type 2 DM who had been divided into a metformin group and a non-metformin group. Comparisons regarding pathological type, incidence of metastasis, expression of CD133 and β-catenin were conducted between the two groups. We explored the synergistic effects of metformin in combination with 5-FU on the proliferation, cell cycle, apoptosis and the proportion of CD133+ cscs of SW620 human colorectal cancer cell lines. The results show that metformin treatment had reverse correlations with the proportion of patients with poorly differentiated adenocarcinoma, the proportion of CD133+ cscs in CRC patients with type 2 DM. Metformin enhanced the antiproliferative effects of 5-FU on CD133+ cscs in SW620 cells. These findings provide an important complement to previous study. Inhibition of the proliferation of CD133+ cscs may be a potential mechanism responsible for the association of metformin use with improved CRC outcomes in CRC patients with type 2 diabetes. Public Library of Science 2013-11-21 /pmc/articles/PMC3836781/ /pubmed/24278407 http://dx.doi.org/10.1371/journal.pone.0081264 Text en © 2013 Zhang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Zhang, Yanfei
Guan, Meiping
Zheng, Zongji
Zhang, Qian
Gao, Fang
Xue, Yaoming
Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients
title Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients
title_full Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients
title_fullStr Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients
title_full_unstemmed Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients
title_short Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients
title_sort effects of metformin on cd133+ colorectal cancer cells in diabetic patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836781/
https://www.ncbi.nlm.nih.gov/pubmed/24278407
http://dx.doi.org/10.1371/journal.pone.0081264
work_keys_str_mv AT zhangyanfei effectsofmetforminoncd133colorectalcancercellsindiabeticpatients
AT guanmeiping effectsofmetforminoncd133colorectalcancercellsindiabeticpatients
AT zhengzongji effectsofmetforminoncd133colorectalcancercellsindiabeticpatients
AT zhangqian effectsofmetforminoncd133colorectalcancercellsindiabeticpatients
AT gaofang effectsofmetforminoncd133colorectalcancercellsindiabeticpatients
AT xueyaoming effectsofmetforminoncd133colorectalcancercellsindiabeticpatients